SEC Filings

Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT^® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

Filing date	Form	Description	View
Jul 22, 2016	CORRESP	CORRESP	View HTML 0001558370-16-006736.pdf 0001558370-16-006736.rtf 0001558370-16-006736.xls
Apr 29, 2015	CERTNAS	CERTNAS	View HTML 9999999997-15-008888.pdf 9999999997-15-008888.rtf
May 10, 2023	ARS/A	ARS/A	View HTML 0001104659-23-058510.pdf 0001104659-23-058510.rtf
Mar 11, 2016	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-16-004066.pdf 0001558370-16-004066.rtf 0001558370-16-004066.xls EX-101.INS - EX-101.INS
Mar 09, 2017	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-17-001547.pdf 0001558370-17-001547.rtf 0001558370-17-001547.xls EX-101.INS - EX-101.INS
Feb 21, 2018	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-18-000862.pdf 0001558370-18-000862.rtf 0001558370-18-000862.xls EX-101.INS - EX-101.INS
Feb 26, 2019	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-19-001094.pdf 0001558370-19-001094.rtf 0001558370-19-001094.xls EX-101.INS - EX-101.INS
Feb 13, 2020	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-20-000784.pdf 0001558370-20-000784.rtf 0001558370-20-000784.xls EX-101.SCH - EX-101.SCH
Feb 17, 2021	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-21-001141.pdf 0001558370-21-001141.rtf 0001558370-21-001141.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
Feb 17, 2022	10-K	Annual report which provides a comprehensive overview of the company for the past year	View HTML 0001558370-22-001316.pdf 0001558370-22-001316.rtf 0001558370-22-001316.xls EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA

Investors & Media

Transformative science, targeted medicines

SEC Filings

Pagination